Despite these advances, existing studies remain fragmented, focusing narrowly on isolated cancer types or mechanistic pathways; no systematic study has explored DHCR7's pan‐cancer immunological relevance or its potential as a biomarker for immunotherapy response, leaving a pivotal knowledge gap in immuno‐oncology. Here, DHCR7 is linked to cancer.